The cord blood banking industry has grown increasingly complex over the past few years. While rates of growth within the industry were robust during the early 2000’s, it is no longer the rapid growth market that it used to be. There is now increased market competition, tighter regulatory standards, more substantial government oversight, and increased public scrutiny given toward cord blood industry practices.
[Read more…]
Tasked with Meeting Increasingly Large Sales Goals for Your Stem Cell Company?
This was a major year for stem cells, as we saw the first ever induced pluripotent stem cell (iPSC) trial in humans, as well as several large mergers and acquisitions within the stem cell industry. One of the most prominent was the buyout of Life Technologies by industry behemoth Thermo Fisher Scientific.
There were also major technical advances that occurred, including notable advances made by scientists at the Harvard Stem Cell Institute (HSCI) toward the creation of human insulin-producing cells from human embryonic stem cells, as well as advances in the bio-fabrication of human tissues using 3-D cell printing technology, led by Guohao Dai of the Rensselaer Polytechnic Institute, among others.
[Read more…]
How Congressional Support for Cord Blood Banking is Changing
While support for the private cord blood banking industry is mixed among parents and obstetricians, the industry appears to be gaining support on the legislative front. A major congressional decision is underway, as the “Family Cord Blood Banking Act” was introduced to the 113th Congress.
[Read more…]
Business of Commercializing Induced Pluripotent Stem Cells [Infographic]
As a provider of induced pluripotent stem cell (iPSC) products and technologies, you need to make effective product development decisions, generate improved revenues, and take market share from your competition.
To do this, you need to be educated about prevailing market conditions. This involves knowing which stem cell types are showing the most promise and understanding methods through which these cells could be commercialized.
Stem cells are still a relatively new discovery, as the first stem cells were discovered in human cord blood in 1978, the first mouse embryonic stem cells were derived in 1981, and it was not until 2006 that induced pluripotent stem cells (iPSCs) were produced for the first time.
[Read more…]
iPSC Market: 3 Major Market Forces (and Why You Should Care) | Infographic
The induced pluripotent stem cell (iPSC) market first emerged in 2006, when iPSC technology was pioneered by Shinya Yamanaka’s lab at Kyoto University in Japan. The shocking discovery that the introduction of four transcription factors into adult cells could convert them into pluripotent stem cells sent waves of excitement throughout the scientific community.
This landmark event came to represent one of the greatest stem cell research discoveries of all time and was memorialized in 2012, when Dr. Yamanaka and Sir John Gurdon were awarded the Nobel Prize “for the discovery that mature cells can be reprogrammed to become pluripotent.”
iPSC technology has since revolutionized how stem cells are derived, differentiated, and acquired in industrial quantities. It has also dramatically affected our understanding of how human cells and organisms develop.
[Read more…]
- « Previous Page
- 1
- …
- 7
- 8
- 9